Olivia Vizier

Some venture firms are pumping money into publicly traded biotechnology companies, as falling share prices prompt these investors to expand their search for bargains to the public markets.

A vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, ELI-002, is showing promising early study results — but any potential broad commercial availability of the drug is likely several years away, as one researcher tells CURE®.

As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Lumos Pharma is dedicated to transforming the treatment landscape for rare pediatric diseases like PGHD. Lumos Pharma’s approach is not just about creating new drugs; it’s about rethinking the entire patient experience, prioritizing ease of use and minimizing the treatment burden on young patients and their families. Their work exemplifies a broader shift in the

Innovation in the HIV treatment landscape is playing a role in addressing medication adherence. In recent years, long-acting injectable antiretroviral monthly and bi-monthly treatment options have been approved – a welcome alternative for people living with HIV. We are now on the cusp of it coming full circle from the days when patients took multiple

Elicio Therapeutics on Thursday began treating patients with KRAS-mutant pancreatic ductal carcinoma in the Phase II portion of the AMPLIFY-7P trial in which it is testing the cancer vaccine ELI-002 7P as an adjuvant treatment.

With gonorrhea’s rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.

Life Biosciences are specifically focused on restoring and prolonging one’s healthspan by targeting the underlying biology of ageing.

MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million.

In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process.

MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million.

MindMed has announced positive topline results from its phase 2b clinical trial of MM-120 in generalized anxiety disorder, according to a company press release.

Araris currently focuses on oncological advancements. Philipp Spycher, the Co-Founder and CSO, leads this strategic vision, driving a shift in targeted cancer therapies.

The most obvious variability, according to Akihiro Ko, CEO and cofounder of Elixirgen Therapeutics, is the disease severity and the condition of each patient.

This was more than an exercise in academic research. Driven by the recognition that vaccines and immunotherapy were not as effective as expected, the newly minted DeMuth co-founded Elicio Therapeutics, Inc. to explore why that was.

What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.

eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance to treatment.

Elicio Therapeutics, outlined the SITC presentation on ELI-002 and plans for future cancer vaccine development.

The reason that I joined Elicio was in part because my father had KRAS-mutated colorectal cancer.

Capricor Therapeutics, for instance, is developing cell and exosome-based technologies to treat or prevent a broad range of diseases.

Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of action.

In this episode of Breakthrough Economy, MindMed CEO Robert Barrow chats with Host Jen Rogers about how his company, which was the first psychedelic pharmaceutical company to go public, is working to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.

Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.

Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease.

Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.

This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.

Effector Therapeutics is working on selective translation regulator inhibitors (STRIs).

GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection

GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection.